(Adnkronos) - “L’Rsv è un virus che colpisce tutti i bambini piccoli indipendentemente dalle condizioni di salute. Le armi per proteggerci dall’Rsv sono diverse, le aziende stanno lavorando tanto su questo. Gli anticorpi monoclonali sono la scelta migliore. L’Ue ha approvato recentemente il Nirsevimab, il primo anticorpo monoclonale. Può essere somministrato a tutti i bambini con una dose che li protegge per tutta la stagione” Così Chiara Azzari, Professore ordinario di pediatria e immunologa presso l’ospedale pediatrico Meyer di Firenze a margine del Simposio “Da un Piano Nazionale di Vaccinazione a un Piano Nazionale di Immunizzazione – Vecchie e Nuove Sfide della Prevenzione Pediatrica”.
Category
🗞
NewsTranscript
00:00 RSV is a virus that affects all children in a very democratic way.
00:08 There are no categories of risk.
00:10 That's why it's important to protect everyone.
00:13 Because if we look at the children in hospital,
00:16 they are not children who have had diseases before,
00:19 who have risk conditions.
00:20 They are children who were perfectly healthy before,
00:23 they just have the problem of being very small.
00:26 So it affects all small children,
00:28 regardless of their previous health conditions.
00:31 That's why we have to protect everyone.
00:34 The weapons we have at our disposal to protect ourselves against RSV are different.
00:39 Companies are working a lot on this,
00:41 both vaccines for children,
00:43 for pregnant mothers,
00:45 so that mothers can pass antibodies to children,
00:48 but also monoclonal antibodies.
00:50 Monoclonal antibodies are well-made antibodies,
00:53 ready-made, that can be supplied to children.
00:56 If we think about something very important,
00:59 that is, the vast majority of children get sick under the age of three,
01:05 we already understand that it is difficult to protect them by giving them a vaccine.
01:10 We have to give them ready-made antibodies.
01:13 That's why monoclonal antibodies are probably the best choice,
01:17 because we give them at the beginning of the season,
01:20 that is, when they are needed.
01:21 We can give them to all children
01:23 and we don't need time.
01:27 Instead, the vaccine would require some immunity for each child.
01:32 Yes, Europe has recently approved one of these monoclonals.
01:37 The first one we will have available is called NIR-Sevimab.
01:41 This is a monoclonal that can be given to all children,
01:46 with a dose like a vaccine,
01:48 and that protects them for the entire season of the respiratory syndrome.
01:54 That is, they are given for example in October,
01:56 and then the child is protected for the entire season until April.